Psyence Group Inc. · OTC:PSYGF
Psyence — Psyence Therapeutics — SPAC Merger (February 2023)
21 slides from Psyence's SPAC merger presentation, Feb 3, 2023
Slide 1: Corporate Presentation
CSE: PSYG | OTCQB: PSYGFCorporate Presentation
Slide 2: Disclaimer and Forward-Looking Statements
1CSE: PSYG | OTCQB: PSYGF Corporate Presentation This Presentation (this “Presentation”) does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes. The information contained in this Presentation has been prepared for the
Slide 3: Forward-Looking Statements and Industry and Market Data
2CSE: PSYG | OTCQB: PSYGF Corporate Presentation The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Registration Statement referenced herein and other documents file
Slide 4: Introducing the Leadership Teams
3CSE: PSYG | OTCQB: PSYGF Corporate Presentation Introducing the Leadership Teams Proven Track Record in Innovation with Extensive Operating Experience Marc Balkin CHIEF EXECUTIVE OFFICER • Partner, DiGame • Former Partner, HassoPlattner Ventures • Served on investment committees of Enablis , First
Slide 5: Domain Experts in Partnership with Experienced SPAC Dealmakers
4CSE: PSYG | OTCQB: PSYGF Corporate Presentation Domain Experts in Partnership with Experienced SPAC DealmakersLeveraging FTAC Experience FTAC Olympus Acquisition Corp.$750mm merged with PayoneerFTAC Parnassus Acquisition Corp.$250mm SPACFTAC Zeus Acquisition Corp. $440mm SPACLocust Walk Acquisition
Slide 6: Acquisition Target Drug Development
5CSE: PSYG | OTCQB: PSYGF Corporate Presentation Acquisition Target Drug Development
Slide 7: Executive Summary
6CSE: PSYG | OTCQB: PSYGF Corporate Presentation Executive Summary Licensed producer of natural psilocybinDrug DevelopmentNewcourtAcquisition Corp. and Psyence Therapeutics entered into a Business Combination Agreement on January 9th, 2023•Resulting cash in the Combined Company will be $20M:•Complet
Slide 8: Psychedelics are making headlines: Market Disruptor
7CSE: PSYG | OTCQB: PSYGF Corporate Presentation Psychedelics are making headlines: Market Disruptor
Slide 9: Psyence is changing the face of palliative care treatment
8CSE: PSYG | OTCQB: PSYGF Corporate Presentation *Source: Global Psychedelic Therapeutics Market (insightaceanalytic.com) ** Pallicybin–Psyence’sproprietary Psilocybin $10.4B USD 2027Psyenceis changing the face of palliative care treatmentNaturally Derived Plant based PsilocybinIn Licensed IP Exclus
Slide 10: Psychedelic peer comparison by market cap and clinical phase
9CSE: PSYG | OTCQB: PSYGF Corporate Presentation Market Cap (mm)Pre-clinicalPhase IPhase IIPhase III8.64.4 8.916.8 23.363.984.7100.9331.7447.9Commentary•Psyence’s core focus is on psilocybin-assisted psychotherapy for palliative care•The global palliative care market is massive; projected to reach $
Slide 11: Large Palliative Care Market with Robust CAGR
10CSE: PSYG | OTCQB: PSYGF Corporate Presentation Large Palliative Care Market with Robust CAGR Cancer = 37% of Total PC Market Partial Accessible MarketGlobal Palliative Care Market $28.6B with 9.8% CAGR (2030)Number of Cancer Patients Globally 21.7M (2030)*Source: Global Psychedelic Therapeutics M
Slide 12: Psychedelic-Assisted Psychotherapy (PAP)
11CSE: PSYG | OTCQB: PSYGF Corporate Presentation Corporate PresentationPsychedelic-Assisted Psychotherapy (PAP)Psilocybin Assisted Psychotherapy (usually 6-8 weeks in total) Introduction to therapist and processIntention setting Psychedelic session with therapist for 6-8 hoursIntegration sessionInt
Slide 13: UK Clinical Trial Phase IIa
12CSE: PSYG | OTCQB: PSYGF Corporate Presentation UK Clinical Trial Phase IIaPsyence’sclinical trial program is focused on assessing the safety and efficacy of psilocybin-assisted psychotherapy for the treatment of adjustment disorder* due to an incurable cancer diagnosis versus psychotherapy alone.
Slide 14: Proposed Phase IIb Trial Format
13CSE: PSYG | OTCQB: PSYGF Corporate Presentation Proposed Phase IIb Trial Format A Phase IIb Randomized, Double-blind, Placebo-controlled, Study of the Effects of Psilocybin-assisted Psychotherapy on Adjustment Disorder in terminal cancer patients:•Assess safety, efficacy and tolerability of PEX010
Slide 15: Updated Regulatory Pathway to Approval
14CSE: PSYG | OTCQB: PSYGF Corporate Presentation Updated Regulatory Pathway to Approval Phase IIB, to be conducted in Australia. H1 2023Commencing Q2 2023H1 2024H2 20241. Pre -IND2. Phase IIb 3. Open IND4. 2 x PivotalPhase IIIs(Can be run concurrently)
Slide 16: Psyence Therapeutics Strategic R&D Plan 2023-2025
15CSE: PSYG | OTCQB: PSYGF Corporate Presentation Pre-clinicalObservationalPhase IPhase IIPhase III2023 –2025 Psyence Therapeutics Strategic R&D Plan Clinical Trial Phases* In Planning# Details to be released after results knownFPFV= First Patient, First VisitFSR= Final Study ReportPalliative Care –
Slide 17: Differentiated Strategy
16CSE: PSYG | OTCQB: PSYGF Corporate Presentation Differentiated StrategyPsyence Target IndicationAdjustment Disorderassociated with Terminal Cancer DiagnosisAdjustment disorder is aserious condition affecting 40% of patients with a terminal diagnosis. Psychedelic Sector** •First mover in Palliative
Slide 18: Psyence's Intellectual Property within Drug development
17CSE: PSYG | OTCQB: PSYGF Corporate Presentation Psyence’sIntellectual Property within Drug developmentMay2022Q42022Q42022 Regulatory ProtectionData and Marketing Exclusivity:•First indication with Molecule will be granted protection from any generic entry for periods up to 10 years•Upon approval,
Slide 19: Transaction Overview
18CSE: PSYG | OTCQB: PSYGF Corporate Presentation Transaction Overview Transaction HighlightsDeal Structure •PsyenceGroup shareholders are expected to retain a pro forma ownership of approximately 33% of the combined company before the effects of warrants and final redemptions at closing Valuation•T
Slide 20: In Summary
19CSE: PSYG | OTCQB: PSYGF Corporate Presentation Licensed producer of natural psilocybinDrug DevelopmentIn Summary•Psyence Therapeutics, developing natural psilocybin for the treatment of Adjustment Disorder in palliative care, is combining with NewcourtAcquisition Corp.•The two companies entered i
Slide 21: Risk Factors Relating to Psyence's Business
20CSE: PSYG | OTCQB: PSYGF Corporate Presentation Risk Factors Relating to Psyence’sBusinessThe Company’s operating and financial forecasts, which are subject to various known and unknown contingencies and factors outside of the Company’s control, may not prove accurate and the Company may not achie